Rajiv Malik
President at Viatris
Thanks, Scott, and good morning, everyone. Our strong performance this quarter highlights the momentum of our business like never before and further reinforces the predictability of our base business, which is well-diversified from a geography, as well as portfolio point-of-view. The performance of the last 10 quarters demonstrates that our business model of bringing access has never relied on any one product or any one market. The strength of our underlying business is enabling us to position the company well for Phase 2 growth.
Our continued new product revenue performance is another key feature of our plan, and for this year again, we remain on-track to deliver on our expectation of approximately $500 million U.S. of new product revenue. As I provide commercial segment highlights for the quarter, I will be making certain comparisons on an operational basis, which excludes the negative impact of foreign currency debts versus the plan that supports our financial guidance. In addition, I will be making certain comparisons to our Q2 '22 results on divestitures adjusted operational basis as defined in our earnings release. This quarter, total net sales grew 1.5% on an operational basis due to a strong performance across various geographies and product portfolios. We believe achieving this top-line growth for the first time as Viatris to flex the power of our platform, well-thought-out strategy and our consistent execution.
Let me get into our commercial segment highlights. Our well-balanced business of developed markets where brands make up approximately 55% of our net sales, in quarter two, delivered another strong quarter. Europe performed ahead of our expectations, delivering 2% year-over-year growth on an operational basis. Italy, Spain and U.K. as well as several other markets drove the strong momentum for the quarter as solid performance of generics in Europe was another contributing factor.
Our North-America business was flat year-over-year on an operational basis and also performed ahead of expectations. Generics delivered a better-than-expected performance, led by lenalidomide, Wixela and [Indecipherable]. Our brand business was supported by strong demand in epinephrine market and Yupelri, which grew 12% this year over the last year. Yupelri, which is the only nebulized long-acting muscarinic clinic agent available in the market continues to show significant growth and enjoys about a 30% market share in the broader, long-acting, nebulized COPD market, and is well on its way to become the number-one product in this space.
Our new launches in North America are on-track, and we are very excited about our recent introduction of Breyna, our generic to Symbicort. We expect that this launch will be 180 days first-to-file generic exclusivity, which is subject to FDA's future determination of the issue if and when another ANDA filer becomes eligible for final approval. For the second half of the year, we believe the developed market segment is poised for year-over-year growth, and we remain confident to meet or exceed our full-year expectation of both North-America and Europe.
Emerging markets had another strong quarter and delivered 10% year-over-year operational growth led by stronger-than-expected performance of genetics and brands like Lipitor, Lyrica and Celebrex. Emerging Asia and Middle-East was strong performing geographies. We remain confident for this segment to deliver better-than-expected for the full year and grow versus the prior year. JANZ performed in-line with our expectations, and we anticipate continuing to meet our expectations for the full year.
In Greater China, we delivered 1% operational growth in this quarter, primarily due to Viagra and other retail driven products in China. We remain on track to meet our planned expectations for the year. Our team in China has been focused on continuing to expand our presence in the private channel, while navigating and managing that evolving policy dynamics on the ground. We have also been very focused on building and expanding our pipeline of new products in China. To that end, our NDAs for Dymista and performance [Phonetic] received approval from FDA in this quarter. In addition to this, our partners NDA for Tyrvaya was also accepted, while eight other products are under active review.
Moving to eye care, Tyrvaya's launch continued to progress as planned in its second-quarter as part of Viatris. During the quarter, Tyrvaya's bridge program was optimized to drive increased value per script, and achieved the highest quarterly TRx launch to date. Furthermore, we remain focused on maximizing its potential, including increasing share of Medicare prescriptions, driving continued growth in total prescriptions and launching the brand's first direct-to-consumer campaign in the fourth quarter, which together we believe provides support for our near and longer-term expectations for the brand.
We are also excited by the continued progress of our eyecare pipeline, which is aimed at addressing a range of vision related disorders. Our NDA review of MR-140 for the reversal of mydriasis program is under active review with a PDUFA date of September 28th of this year. We have completed patient enrollment in the first pivotal Phase 3 trial of MR-141 for the treatment of presbyopia and expect top-line data in Q3 of this year. And we remain on-track to initiate the second Phase 3 trial later this year.
We have initiated patient enrollment in the first Phase 3 study, MR-148 for the treatment of dry eye disease, expect top-line data in '24. We are initiating a Phase 3 program of MR-139 for for the treatment of blepharitis later this year. MR-142 for night vision disturbances and MR-146 for neurotrophic keratopathy also remain on track.
Switching to other pipeline updates and beginning with the news we announced today around GA Depot, the FDA has accepted for review our recently submitted NDA and assigned a PDUFA date of March '24. Our application is backed by Phase 3 efficacy and safety data, and we believe GA Depot could improve patient experience through fewer injections, greater tolerability and increased compliance. We are feeling very confident in the strength of our GA Depot clinical program, and continue to believe that we remain on track to launch in the second half of '24. We are equally excited about the potential opportunity to also bring this product to patients in Europe, which we expect to file later this year.
Our Botox biosimilar program is progressing well from the development, characterization as well as validation of drug substance and drug product perspective. We remain on track to file our IND by the end of this year. Our Phase 3 study for our Zulin low dose program in USA remains on track with nearly 800 of the planned 1200 women enrolled. We are targeting completion of enrollment by March 24, and our Phase 3 study for Effexor, generalized anxiety disorder in Japan is well on schedule, and we are targeting an NDA filing in the first half of '25.
Lastly, all our complex injectable programs are moving ahead as planned. Before I turn the call to Sanjeev, I want to thank our colleagues for another strong quarter and consistent performance. With that, Sanjeev.
